AMRN Amarin Corporation plc - American Depositary Shares
NASDAQ · Biotechnology · SEC EDGAR पर देखें ↗ बंद अक्ट 2, 2026 10-K/10-Q जुल 29, 2026
$12.35
· 52 सप्ताह की सीमा का %
· निम्न से ऊपर
· उच्च तक
$12.3252w निम्न
$20.9052w उच्च
मार्केट कैप (MRQ)
$5.19B
P/E (TTM)
-176.4
EPS (TTM)
$-0.07
राजस्व (TTM)
$186M
आपके बैज
52W रेंज
$12–$21
विश्लेषक रेटिंग
SELL
मूल्य लक्ष्य
$12
P/E
-176.4
ROE
-6.0%
शुद्ध लाभ मार्जिन
-14.6%
आपकी बैज स्ट्रिप खाली है — इस पेज पर कहीं भी एक मीट्रिक पिन करें।
AMRN स्टॉक स्नैपशॉट मूल्य, बाजार पूंजीकरण, P/E, EPS, ROE, ऋण/इक्विटी, 52-सप्ताह की सीमा
मूल्य
$12.35
मार्केट कैप (MRQ)
$5.19B
P/E (TTM)
-176.4
EPS (TTM)
$-0.07
राजस्व (TTM)
$186M
ROE (TTM)
-6.0%
52W रेंज
$12–$21
AMRN स्टॉक मूल्य चार्ट तकनीकी संकेतकों के साथ दैनिक OHLCV — पैन, ज़ूम और अपना दृश्य कस्टमाइज़ करें
सीमा
बार
बार ग्रैन्युलैरिटी चयनित अवधि के अनुसार अनुकूलित होती है — बार के लिए ओपन/हाई/लो/क्लोज देखने के लिए चार्ट पर होवर करें।
स्टॉक विभाजन
| एक्स-डेट | स्प्लिट | प्रकार |
|---|---|---|
| 11 अप्रैल 2025 | 1-for-20 | रिवर्स |
| 18 जनवरी 2008 | 1-for-10 | रिवर्स |
| 19 अक्टूबर 1998 | 1-for-10 | रिवर्स |
Amarin Corporation plc - American Depositary Shares के बारे में विकिपीडिया से कंपनी का अवलोकन
Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid.
In July 2012, their lead-candidate drug named Vascepa (AMR-101) received FDA-approval, competing against GlaxoSmithKline's Lovaza.
History
Amarin Corporation plc (formerly Ethical Holdings plc) was originally incorporated in England as a private limited company on March 1, 1989, and later re-registered as a public company on March 19, 1993. In 2002, the company suffered losses worth $37 million; 2003 losses exceeded $19 million. As of 2005, it was developing neurology drugs. It developed Miraxion to treat serious hereditary neurodegenerative disease.
In December 2007, Amarin acquired Ester Neurosciences Limited for US$8.1 million. In 2011, CEO Joe Zakrzewski said that the company would like to first work on building its infrastructure out to commercialize the drug in the United States.
Products and development
Vascepa (USA) / Vazkepa (EU)
Amarin´s sole product VASCEPA® came on the market in 2013 for triglyceride levels >=500 milligrams per deciliter. In December 2019, the FDA approved "...the use of Vascepa (icosapent ethyl) as an adjunctive (secondary) therapy to reduce the risk of cardiovascular events among adults with elevated triglyceride levels (a type of fat in the blood) of 150 milligrams per deciliter or higher. Patients must also have either established cardiovascular disease or diabetes and two or more additional risk factors for cardiovascular disease....Vascepa is the first FDA approved drug to reduce cardiovascular risk among patients with elevated triglyceride levels as an add-on to maximally tolerated statin therapy.
Furthermore, VASCEPA® is in use in clinical trials by 3rd parties to see, if it has an effect on Alzheimer, Colon Cancer, Nonalcoholic Steatohepatitis (NASH), and other diseases.
HLS Therapeutics, Amarin´s license partner in Canada, presented results of their COVID-19 clinical trial for Vascepa at National Lipid Association Scientific Sessions 2020, December 12. The results demonstrated a 25% reduction of hs-CRP, a biomarker for inflammation. Most people with COVID-19 die, because of a cytokine storm, which causes an uncontrolled and excessive release of pro-inflammatory signaling molecules called cytokines. Two more COVID-19 studies are actually running with Vascepa to validate and proof further benefits.
On January 28, the Committee for Medicinal Products for Human Use gave a positive recommendation for Vazcepa (its name in the EU), which the European Commission finally approved on March 30.
Patent disputes
On March 30, 2020, the designated patent judge in the U.S. District Court for the District of Nevada, Miranda Du, ruled for generic-drug makers Hikma Pharmaceuticals and Dr. Reddy's Laboratories in a lawsuit with Amarin over patents on Amarin's drug, Vascepa. Soon after, on April 2, 2020, Amarin filed an appeal of the ruling. The appeal was lost and an en-banc was also not granted, afterwards. On November 30, three weeks after Hikma Pharmaceuticals started the distribution of their generic version of Vascepa, Amarin filed a complaint of patent infringement against Hikma. On February 11, 2021, Amarin filed a petition for certiorari with the US Supreme Court. On June 21, 2021, the petition was denied.
== Finance ==
स्रोत: विकिपीडिया (अंग्रेज़ी), CC BY-SA 4.0 · विकिपीडिया पर देखें ↗
क्षेत्रHealthcare
उद्योगBiotechnology
कर्मचारी80
देशIE
10-वर्षीय प्रदर्शन राजस्व, शुद्ध आय, मार्जिन और ईपीएस रुझान
राजस्व$214M2016-12-31 → 2025-12-31
EPS$-0.092016-12-31 → 2025-12-31
फ्री कैश फ्लो·2016-12-31 → 2020-12-31
शुद्ध मार्जिन-14.6%2016-12-31 → 2025-12-31
मूल्यांकन और अनुपात
मूल्यांकन P/E, P/S, P/B, EV/EBITDA अनुपात — क्या स्टॉक महंगा है या सस्ता?
| मेट्रिक | 5Y रुझान | AMRN | 5Y औसत | सहकर्मी माध्यिका | निर्णय |
|---|---|---|---|---|---|
| P/E (TTM) | -176.45Y औसत ≈591.4 | ≈591.4 | · | · | |
| P/S (TTM) | 27.95Y औसत ≈22.7 | ≈22.7 | · | · | |
| P/B (MRQ) | 11.75Y औसत ≈11.3 | ≈11.3 | · | · | |
| Price / Cash Flow (मूल्य / नकदी प्रवाह) | 764.05Y औसत ≈589.2 | ≈589.2 | · | · | |
| मूल्य / मूर्त पुस्तक (MRQ) | 12.05Y औसत ≈18.7 | ≈18.7 | · | · |
सहकर्मी माध्यिका को प्रति मीट्रिक मानकीकृत आधार पर गणना की जाती है और यह हमेशा इस स्टॉक के लिए दिखाए गए TTM/MRQ आधार से मेल नहीं खा सकती है।
लाभप्रदता सकल, परिचालन और शुद्ध मार्जिन; ROE, ROA, ROIC
| मेट्रिक | 5Y रुझान | AMRN | 5Y औसत | सहकर्मी माध्यिका | निर्णय |
|---|---|---|---|---|---|
| सकल मार्जिन (TTM) | 42.0%5Y औसत ≈48.7% | ≈48.7% | · | · | |
| परिचालन मार्जिन (TTM) | -21.9%5Y औसत ≈-28.6% | ≈-28.6% | · | · | |
| EBITDA Margin (EBITDA मार्जिन) | -23.5%5Y औसत ≈-28.6% | ≈-28.6% | · | · | |
| प्रीटैक्स मार्जिन (TTM) | -13.7%5Y औसत ≈-22.7% | ≈-22.7% | · | · | |
| शुद्ध लाभ मार्जिन (TTM) | -14.6%5Y औसत ≈-24.5% | ≈-24.5% | · | · | |
| ROA (TTM) | -4.2%5Y औसत ≈-7.8% | ≈-7.8% | · | · | |
| ROE (TTM) | -6.0%5Y औसत ≈-11.8% | ≈-11.8% | · | · | |
| ROIC | -11.8%5Y औसत ≈-15.1% | ≈-15.1% | · | · |
वित्तीय स्वास्थ्य ऋण, तरलता, शोधन क्षमता — बैलेंस शीट की मजबूती
| मेट्रिक | 5Y रुझान | AMRN | 5Y औसत | सहकर्मी माध्यिका | निर्णय |
|---|---|---|---|---|---|
| वर्तमान अनुपात (MRQ) | 3.75Y औसत ≈3.1 | ≈3.1 | · | · | |
| त्वरित अनुपात (MRQ) | 2.55Y औसत ≈2.1 | ≈2.1 | · | · | |
| Interest Coverage (ब्याज कवरेज) | -7167.15Y औसत ≈-9576.5 | ≈-9576.5 | · | · |
विकास राजस्व, EPS और शुद्ध आय वृद्धि: YoY, 3Y CAGR, 5Y CAGR
| मेट्रिक | 5Y रुझान | AMRN | 5Y औसत | सहकर्मी माध्यिका | निर्णय |
|---|---|---|---|---|---|
| Revenue YoY (राजस्व YoY) | -6.6%5Y औसत ≈-18.1% | ≈-18.1% | · | · | |
| Revenue CAGR 3Y (राजस्व CAGR 3Y) | -16.7%5Y औसत ≈-21.4% | ≈-21.4% | · | · | |
| Revenue CAGR 5Y (राजस्व CAGR 5Y) | -19.0% | · | · | · |
पूंजी दक्षता एसेट टर्नओवर, इन्वेंटरी टर्नओवर, प्राप्य टर्नओवर
| मेट्रिक | 5Y रुझान | AMRN | 5Y औसत | सहकर्मी माध्यिका | निर्णय |
|---|---|---|---|---|---|
| Asset Turnover (परिसंपत्ति टर्नओवर) | 0.35Y औसत ≈0.3 | ≈0.3 | · | · | |
| Receivables Turnover (प्राप्य टर्नओवर) | 1.75Y औसत ≈1.9 | ≈1.9 | · | · | |
| Revenue / Employee (राजस्व / कर्मचारी (रिपोर्ट की गई हेडकाउंट, यफाइनांस)। व्युत्पन्न — संग्रहीत SEC-XBRL अवधारणा नहीं है।) | ≈$2.7M | · | · | · |
मान · ≈ 5Y औसत · उद्योग माध्य · माध्य के सापेक्ष निर्णय
Earnings History EPS वास्तविक बनाम अनुमान, आश्चर्य %, बीट दर, अगली आय तिथि
औसत आश्चर्य
49.9%
अगली रिपोर्ट
अक्ट 27, 2026
| Period | रिपोर्ट | EPS Actual | EPS अनुमान | आश्चर्य |
|---|---|---|---|---|
| 30 जून 2026 | जुल 28, 2026 | $-0.02 | $-0.01 | -96.1% |
| 31 मार्च 2026 | $-0.09 | $0.09 | -203.8% | |
| 31 दिसमबर 2025 | $0.01 | $0.00 | — | |
| 30 सितमबर 2025 | $0.08 | $-0.58 | 113.8% | |
| 30 जून 2025 | $0.66 | $-0.18 | 466.3% | |
| 31 मार्च 2025 | $-0.76 | $-0.58 | -30.7% |
पूर्ण मौलिक सभी मेट्रिक्स प्रति वर्ष — आय विवरण, बैलेंस शीट, नकदी प्रवाह
आय विवरण
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $214M | $229M | $307M | $369M | $583M | $614M | $430M | $229M | $181M | $130M | $82M | $54M | |
| Cost of Revenue | · | · | · | · | $121M | $131M | $96M | $55M | $45M | $34M | $28M | $20M | |
| Gross Profit | $121M | $81M | $166M | $242M | $462M | $483M | $334M | $175M | $136M | $96M | $54M | $34M | |
| R&D Expense | $20M | $21M | $22M | $30M | $29M | $39M | $34M | $56M | $47M | $50M | $51M | $50M | |
| SG&A Expense | $115M | $152M | $200M | $304M | $408M | $463M | $324M | $227M | $135M | $111M | $101M | $79M | |
| Operating Expenses | $171M | $173M | $233M | $348M | $451M | $502M | $358M | $283M | $182M | $161M | $152M | $130M | |
| Operating Income | $-50M | $-92M | $-68M | $-106M | $11M | $-20M | $-24M | $-108M | $-46M | $-66M | $-98M | $-96M | |
| Interest Expense | $7.0K | $7.0K | $8.0K | $15.0K | $129.0K | $3M | $7M | $9M | $10M | $19M | $20M | $19M | |
| Interest Income | $11M | $13M | $12M | $3M | $1M | $5M | $8M | $1M | $429.0K | $234.0K | $132.0K | $96.0K | |
| Other Non-op | $3M | $1M | $2M | $-740.0K | $-302.0K | $104.0K | $-75.0K | $-326.0K | $74.0K | $-482.0K | $-228.0K | $4M | |
| Pretax Income | $-36M | $-77M | $-54M | $-104M | $11M | $-17M | $-22M | $-116M | $-55M | $-76M | $-118M | $-59M | |
| Income Tax | $3M | $5M | $5M | $2M | $4M | $745.0K | $164.0K | $96.0K | $13M | $10M | $-3M | $-3M | |
| Net Income | $-39M | $-82M | $-59M | $-106M | $8M | $-18M | $-23M | $-116M | $-68M | $-86M | $-115M | $-56M | |
| EPS (Basic) | $-0.09 | $-0.20 | $-0.15 | $-0.26 | $0.02 | $-0.05 | $-0.07 | $-0.39 | $-0.25 | $-0.41 | $-0.83 | $-0.32 | |
| EPS (Diluted) | $-0.09 | $-0.20 | $-0.15 | $-0.26 | $0.02 | $-0.05 | $-0.07 | $-0.39 | $-0.25 | $-0.41 | $-0.83 | $-0.36 | |
| Shares (Basic) | 414,984,000 | 410,937,000 | 407,655,000 | 401,155,000 | 395,992,000 | 381,759,000 | 342,538,000 | 297,237,000 | 270,652,000 | 211,874,000 | 180,654,000 | 173,719,000 | |
| Shares (Diluted) | 414,984,000 | 410,937,000 | 407,655,000 | 401,155,000 | 402,480,000 | 381,759,000 | 342,538,000 | 297,237,000 | 270,652,000 | 211,874,000 | 180,654,000 | 173,824,000 | |
| EBITDA | $-50M | $-92M | $-68M | · | · | $-20M | · | $-108M | $-46M | $-66M | $-98M | $-96M |
बैलेंस शीट
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $135M | $121M | $199M | $218M | $219M | $187M | $645M | $249M | $74M | $98M | $107M | $120M | |
| Short-term Investments | $168M | $173M | $121M | $92M | $235M | $314M | · | · | · | · | · | · | |
| Receivables | $127M | $122M | $134M | $131M | $164M | $155M | $116M | $67M | $45M | $20M | $14M | $8M | |
| Inventory | $196M | $166M | $259M | $229M | $235M | $189M | $77M | $58M | $30M | $21M | $19M | $14M | |
| Prepaid Expense | $24M | $13M | $12M | $19M | $22M | $31M | $13M | $3M | $3M | $7M | $3M | $3M | |
| Other Current Assets | · | · | · | · | · | · | · | · | · | · | · | $3M | |
| Current Assets | $650M | $595M | $725M | $689M | $879M | $879M | $855M | $378M | $153M | $146M | $144M | $145M | |
| PP&E (Net) | $12.0K | $16.0K | $114.0K | $874.0K | $1M | $2M | $2M | $63.0K | $28.0K | $78.0K | $243.0K | $381.0K | |
| PP&E (Gross) | $1M | $1M | $1M | $3M | $3M | $4M | $3M | $902.0K | $844.0K | $821.0K | $997.0K | $969.0K | |
| Accum. Depreciation | $1M | $1M | $1M | $2M | $2M | $2M | $1M | $839.0K | $816.0K | $755.0K | $754.0K | $588.0K | |
| Intangibles | $13M | $16M | $19M | $22M | $24M | $14M | $15M | $7M | $8M | $9M | $9M | $10M | |
| Other Non-current Assets | $1M | $1M | $1M | $458.0K | $456.0K | $432.0K | $1M | $174.0K | $174.0K | $741.0K | $174.0K | $3M | |
| Total Assets | $671M | $685M | $832M | $886M | $1.07B | $966M | $882M | $386M | $162M | $167M | $173M | $171M | |
| Accounts Payable | $45M | $40M | $53M | $65M | $115M | $106M | $50M | $38M | $25M | $6M | $11M | $9M | |
| Current Liabilities | $194M | $180M | $259M | $259M | $371M | $307M | $242M | $157M | $109M | $76M | $51M | $40M | |
| Capital Leases | $6M | $8M | $9M | $10M | $9M | $9M | $9M | · | · | · | · | · | |
| Other Non-current Liabilities | $11M | $12M | $9M | $8M | $8M | $6M | $4M | $11M | $1M | $710.0K | $335.0K | $386.0K | |
| Total Liabilities | $211M | $199M | $280M | $291M | $401M | $339M | $274M | $233M | $227M | $176M | $301M | $260M | |
| Long-term Debt | · | · | · | · | · | · | $50M | $80M | $92M | $94M | $92M | $105M | |
| Total Debt | · | · | · | · | · | $0 | · | $80M | $93M | $101M | $106M | $105M | |
| Common Stock | $310M | $305M | $303M | $299M | $294M | $290M | $269M | $247M | $209M | $207M | $150M | $143M | |
| Paid-in Capital | $1.92B | $1.91B | $1.90B | $1.89B | $1.86B | $1.82B | $1.76B | $1.28B | $978M | · | · | · | |
| Retained Earnings | $-1.71B | $-1.67B | $-1.59B | $-1.53B | $-1.42B | $-1.43B | $-1.41B | $-1.39B | $-1.27B | $-1.20B | $-1.12B | $-970M | |
| Treasury Stock | $67M | $65M | $64M | $62M | $61M | $51M | $36M | $10M | $4M | $1M | $411.0K | $217.0K | |
| Stockholders' Equity | $459M | $486M | $552M | $595M | $667M | $628M | $608M | $152M | $-65M | $-9M | $-129M | $-88M | |
| Liabilities + Equity | $671M | $685M | $832M | $886M | $1.07B | $966M | $882M | $386M | $162M | $167M | $173M | $171M | |
| Shares Outstanding | 416,214,102 | 411,584,851 | 408,824,093 | 408,824,093 | 396,598,008 | 392,538,081 | 360,103,901 | 325,850,013 | 271,022,011 | 269,363,696 | 183,403,263 | 174,590,372 |
नकदी प्रवाह
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | $23.0K | $62.0K | $138.0K | $166.0K | $198.0K | |
| Stock-based Comp | $14M | $18M | $16M | $26M | $37M | $46M | $31M | $19M | $14M | $14M | $14M | $9M | |
| Deferred Tax | · | · | · | · | · | · | · | · | $11M | $9M | $-4M | $-4M | |
| Amort. of Intangibles | $3M | $3M | $3M | $3M | $2M | $1M | $679.0K | $646.0K | $646.0K | $645.0K | $646.0K | $646.0K | |
| Restructuring | $36M | $0 | $11M | $14M | $14M | · | · | · | · | · | · | · | |
| Operating Cash Flow | $7M | $-31M | $7M | $-180M | $-67M | $-22M | $-9M | $-95M | $-33M | $-72M | $-84M | $-75M | |
| CapEx | · | · | · | · | · | $252.0K | $2M | $58.0K | $12.0K | $21.0K | $28.0K | · | |
| Investing Cash Flow | $9M | $-46M | $-26M | $175M | $104M | $-377M | $-2M | $-58.0K | $-12.0K | $-21.0K | · | · | |
| Net Debt Issued | · | · | · | · | · | $-50M | · | $-15M | $-3M | · | · | · | |
| Stock Issued | · | · | · | · | · | · | $440M | $265M | · | $65M | · | · | |
| Stock Repurchased | · | · | · | · | · | · | · | · | · | · | $194.0K | · | |
| Net Stock Activity | · | · | · | · | · | · | · | $265M | · | $65M | $-194.0K | · | |
| Financing Cash Flow | $-2M | $-1M | $230.0K | $-379.0K | $-5M | $-59M | $410M | $271M | $8M | $63M | · | · | |
| Net Change in Cash | $14M | $-78M | $-18M | $-5M | $32M | $-458M | $398M | $176M | $-25M | $-9M | $-13M | $-72M | |
| Taxes Paid | $1M | $4M | $2M | $-2M | $4M | $-207.0K | $-67.0K | · | · | · | · | · | |
| Free Cash Flow | · | · | · | · | · | $-22M | · | $-95M | $-33M | $-72M | $-85M | · | |
| Levered FCF | · | · | · | · | · | $-25M | · | $-104M | $-45M | $-93M | $-104M | · |
लाभप्रदता
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 56.6% | 35.6% | 53.9% | · | · | 78.6% | · | 76.2% | 75.2% | 73.6% | 65.9% | 62.2% | |
| Operating Margin | -23.5% | -40.2% | -22.0% | · | · | -3.2% | · | -47.2% | -25.1% | -50.4% | -120.1% | -177.0% | |
| Net Margin | -18.2% | -35.9% | -19.3% | · | · | -2.9% | · | -50.8% | -37.5% | -66.4% | -140.9% | -104.0% | |
| Pretax Margin | -16.9% | -33.8% | -17.5% | · | · | -2.8% | · | -50.8% | -30.3% | -58.7% | -144.7% | -109.2% | |
| EBITDA Margin | -23.5% | -40.2% | -22.0% | · | · | -3.2% | · | -47.2% | -25.1% | -50.4% | -120.1% | -177.0% | |
| ROA | -5.7% | -10.8% | -6.9% | · | · | -1.9% | · | -42.5% | -41.3% | -50.8% | -66.9% | -26.6% | |
| ROE | -8.4% | -16.2% | -10.7% | · | · | -2.9% | · | -234.1% | 183.0% | 124.9% | 105.9% | 92.2% | |
| ROIC | -11.8% | -20.1% | -13.5% | · | · | -3.3% | · | -46.6% | -200.8% | -80.6% | 417.0% | -551.6% |
तरलता और शोधन क्षमता
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.3 | 3.3 | 2.8 | · | · | 2.9 | · | 2.4 | 1.4 | 1.9 | 2.8 | 3.6 | |
| Quick Ratio | 2.2 | 2.3 | 1.8 | · | · | 2.1 | · | 2.0 | 1.1 | 1.6 | 2.4 | 3.2 | |
| Debt / Equity | · | · | · | · | · | 0.0 | · | 0.5 | -1.4 | -11.2 | -0.8 | -1.2 | |
| LT Debt / Equity | · | · | · | · | · | · | · | 0.3 | -1.1 | -9.4 | -0.7 | -1.0 | |
| Interest Coverage | -7167.1 | -13113.9 | -8448.5 | · | · | -7.5 | · | -12.2 | -4.7 | -3.5 | -4.9 | -5.2 |
दक्षता
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.3 | 0.4 | · | · | 0.7 | · | 0.8 | 1.1 | 0.8 | 0.5 | 0.3 | |
| Inventory Turnover | · | · | · | · | · | 1.0 | · | 1.2 | 1.8 | 1.7 | 1.7 | 1.2 | |
| Receivables Turnover | 1.7 | 1.8 | 2.3 | · | · | 4.5 | · | 4.1 | 5.5 | 7.7 | 7.5 | 9.4 |
प्रति शेयर
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $1.10 | $1.18 | $1.35 | · | · | $1.60 | · | $0.47 | $-0.24 | $-0.03 | $-0.70 | $-0.51 | |
| Revenue / Share | $0.51 | $0.56 | $0.75 | · | · | $1.61 | · | $0.77 | $0.67 | $0.61 | $0.45 | $0.31 | |
| Cash Flow / Share | $0.02 | $-0.08 | $0.02 | · | · | $-0.06 | · | $-0.32 | $-0.12 | $-0.34 | $-0.47 | $-0.42 | |
| Cash / Share | $0.32 | $0.29 | $0.49 | · | · | $0.48 | · | $0.76 | $0.27 | $0.36 | $0.58 | $0.68 | |
| EPS (TTM) | $-0.09 | $-0.20 | $-0.15 | $-0.26 | $0.02 | $-0.05 | $-0.07 | $-0.39 | $-0.25 | $-0.41 | $-0.83 | $-0.36 |
विकास दरें
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -6.6% | -25.5% | -16.9% | -36.7% | -5.0% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -16.7% | -26.8% | -20.6% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | -19.0% | · | · | · | · | · | · | · | · | · | · | · |
मूल्यांकन (TTM)
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $214M | $229M | $307M | $369M | $583M | $614M | $430M | $229M | $181M | $130M | $82M | $54M | |
| Net Income TTM | $-39M | $-82M | $-59M | $-106M | $8M | $-18M | $-23M | $-116M | $-68M | $-86M | $-115M | $-56M | |
| Market Cap | $5.81B | $4.03B | $7.11B | · | · | $38.39B | · | $88.70B | $21.74B | $16.59B | $6.93B | $3.42B | |
| Enterprise Value | · | · | · | · | · | $37.89B | · | $88.53B | $21.76B | $16.60B | $6.93B | $3.41B | |
| P/E | -155.1 | -49.0 | -116.0 | -93.1 | 3370.0 | -1956.0 | -6125.7 | -697.9 | -320.8 | -150.2 | -45.5 | -54.4 | |
| P/S | 27.2 | 17.6 | 23.2 | · | · | 62.5 | · | 387.0 | 120.0 | 127.6 | 84.8 | 63.1 | |
| P/B | 12.7 | 8.3 | 12.9 | · | · | 61.2 | · | 582.3 | -333.9 | -1831.8 | -53.7 | -38.7 | |
| P / Tangible Book | 13.0 | 8.6 | 13.4 | 17.1 | 41.5 | 62.6 | · | · | · | · | · | · | |
| P / Cash Flow | 863.6 | -130.0 | 1033.9 | · | · | -1765.4 | · | -936.6 | -661.9 | -231.0 | -81.8 | -47.3 | |
| P / FCF | · | · | · | · | · | -1745.2 | · | -936.0 | -661.7 | -231.0 | -81.8 | · | |
| EV / EBITDA | · | · | · | · | · | -1927.7 | · | -818.0 | -477.6 | -252.9 | -70.6 | -35.5 | |
| EV / FCF | · | · | · | · | · | -1722.4 | · | -934.2 | -662.3 | -231.0 | -81.8 | · | |
| EV / Revenue | · | · | · | · | · | 61.7 | · | 386.2 | 120.1 | 127.6 | 84.8 | 62.9 | |
| Earnings Yield | -0.64% | -2.0% | -0.86% | -1.1% | 0.03% | -0.05% | -0.02% | -0.14% | -0.31% | -0.67% | -2.2% | -1.8% |
आय विवरण
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $42M | $45M | $49M | $50M | $73M | $42M | $62M | $42M | $67M | $57M | $75M | $66M | $80M | $86M | $90M | $90M | |
| Gross Profit | $15M | $18M | $23M | $22M | $50M | $25M | $-10M | $16M | $43M | $32M | $45M | $30M | $43M | $48M | $64M | $63M | |
| R&D Expense | $5M | $5M | $5M | $4M | $5M | $5M | $6M | $5M | $5M | $6M | $6M | $5M | $6M | $6M | $5M | $6M | |
| SG&A Expense | $22M | $21M | $20M | $20M | $39M | $37M | $37M | $37M | $39M | $40M | $44M | $45M | $51M | $60M | $68M | $59M | |
| Operating Expenses | $27M | $29M | $29M | $33M | $66M | $42M | $43M | $41M | $43M | $45M | $50M | $51M | $67M | $65M | $73M | $68M | |
| Operating Income | $-12M | $-11M | $-6M | $-11M | $-16M | $-17M | $-53M | $-25M | $-524.0K | $-14M | $-5M | $-21M | $-24M | $-17M | $-10M | $-5M | |
| Interest Income | $3M | $2M | · | · | $3M | $3M | · | · | · | · | · | · | · | · | · | · | |
| Other Non-op | $1M | $188.0K | $3M | $205.0K | $-85.0K | $253.0K | $-754.0K | $265.0K | $145.0K | $2M | $-1M | $-575.0K | $3M | $624.0K | $1M | $511.0K | |
| Pretax Income | $-8M | $-9M | $-853.0K | $-8M | $-13M | $-14M | $-50M | $-22M | $3M | $-9M | $-2M | $-19M | $-18M | $-14M | $-7M | $-4M | |
| Income Tax | $-219.0K | $2M | $371.0K | $-377.0K | $689.0K | $2M | $-1M | $4M | $1M | $1M | $3M | $501.0K | $-355.0K | $2M | $-8M | $1M | |
| Net Income | $-8M | $-11M | $-1M | $-8M | $-14M | $-16M | $-49M | $-25M | $2M | $-10M | $-6M | $-19M | $-18M | $-16M | $856.0K | $-5M | |
| EPS (Basic) | $-0.02 | $-0.03 | $0.00 | $-0.02 | $-0.03 | $-0.04 | $-0.12 | $-0.06 | $0.00 | $-0.02 | $-0.02 | $-0.05 | $-0.04 | $-0.04 | $0.01 | $-0.01 | |
| EPS (Diluted) | $-0.02 | $-0.03 | $0.00 | $-0.02 | $-0.03 | $-0.04 | $-0.12 | $-0.06 | $0.00 | $-0.02 | $-0.02 | $-0.05 | $-0.04 | $-0.04 | $0.01 | $-0.01 | |
| Shares (Basic) | 416,444,000 | 419,054,000 | · | 415,531,000 | 414,477,000 | 413,422,000 | · | 411,150,000 | 410,851,000 | 410,146,000 | · | 408,417,000 | 407,848,000 | 406,177,000 | · | 404,614,000 | |
| Shares (Diluted) | 416,444,000 | 419,054,000 | · | 415,531,000 | 414,477,000 | 413,422,000 | · | 411,150,000 | 411,395,000 | 410,146,000 | · | 408,417,000 | 407,848,000 | 406,177,000 | · | 404,614,000 | |
| EBITDA | $-12M | $-11M | · | $-11M | $-16M | $-17M | · | $-25M | $-524.0K | $-14M | · | $-21M | $-24M | $-17M | · | $-5M |
बैलेंस शीट
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $144M | $131M | $135M | $123M | $148M | $120M | $121M | $157M | $216M | $214M | · | $271M | $233M | $191M | · | $240M | |
| Short-term Investments | $171M | $177M | $168M | $164M | $151M | $162M | $173M | $149M | $91M | $94M | · | $50M | $80M | $113M | · | $63M | |
| Receivables | $93M | $108M | $127M | $127M | $119M | $107M | $122M | $113M | $124M | $116M | · | $122M | $123M | $133M | · | $123M | |
| Inventory | $164M | $184M | $196M | $185M | $171M | $159M | $166M | $224M | $239M | $255M | · | $254M | $227M | $226M | · | $228M | |
| Prepaid Expense | $31M | $26M | $24M | $29M | $17M | $25M | $13M | $7M | $32M | $8M | · | $19M | $43M | $20M | · | $28M | |
| Current Assets | $603M | $626M | $650M | $628M | $607M | $573M | $595M | $650M | $702M | $688M | · | $718M | $706M | $684M | · | $687M | |
| PP&E (Net) | · | · | $12.0K | $13.0K | $14.0K | $15.0K | $16.0K | $24.0K | $49.0K | $81.0K | · | $147.0K | $179.0K | $187.0K | · | $999.0K | |
| PP&E (Gross) | · | · | $1M | · | · | · | $1M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $1M | · | · | · | $1M | · | · | · | · | · | · | · | · | · | |
| Intangibles | $12M | $13M | $13M | $14M | $15M | $16M | $16M | $17M | $18M | $19M | · | $20M | $20M | $21M | · | $22M | |
| Other Non-current Assets | $4M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | · | $1M | $2M | $2M | · | $456.0K | |
| Total Assets | $624M | $646M | $671M | $660M | $670M | $656M | $685M | $751M | $800M | $790M | · | $839M | $860M | $860M | · | $908M | |
| Accounts Payable | $19M | $48M | $45M | $37M | $45M | $46M | $40M | $41M | $54M | $68M | · | $53M | $54M | $59M | · | $93M | |
| Current Liabilities | $164M | $180M | $194M | $182M | $186M | $162M | $180M | $202M | $231M | $224M | · | $267M | $271M | $244M | · | $287M | |
| Capital Leases | $5M | $6M | $6M | $7M | $7M | $8M | $8M | $8M | $8M | $8M | · | $9M | $9M | $10M | · | $10M | |
| Other Non-current Liabilities | $11M | $11M | $11M | $12M | $12M | $12M | $12M | $9M | $9M | $9M | · | $7M | $7M | $9M | · | $10M | |
| Total Liabilities | $181M | $196M | $211M | $201M | $205M | $182M | $199M | $219M | $248M | $244M | · | $286M | $291M | $275M | · | $320M | |
| Common Stock | $315M | $314M | $310M | $310M | $309M | $308M | $305M | $305M | $305M | $305M | · | $302M | $302M | $301M | · | $299M | |
| Paid-in Capital | $1.92B | $1.92B | $1.92B | $1.92B | $1.92B | $1.92B | $1.91B | $1.91B | $1.91B | $1.90B | · | $1.90B | $1.89B | $1.89B | · | $1.88B | |
| Retained Earnings | $-1.73B | $-1.72B | $-1.71B | $-1.71B | $-1.70B | $-1.68B | $-1.67B | $-1.62B | $-1.59B | $-1.60B | · | $-1.58B | $-1.56B | $-1.54B | · | $-1.53B | |
| Treasury Stock | $69M | $69M | $67M | $67M | $67M | $66M | $65M | $65M | $65M | $65M | · | $64M | $63M | $63M | · | $62M | |
| Stockholders' Equity | $444M | $449M | $459M | $459M | $465M | $474M | $486M | $531M | $552M | $546M | $552M | $553M | $569M | $585M | $595M | $588M | |
| Liabilities + Equity | $624M | $646M | $671M | $660M | $670M | $656M | $685M | $751M | $800M | $790M | · | $839M | $860M | $860M | · | $908M | |
| Shares Outstanding | 420,044,022 | 419,594,602 | 416,214,102 | 415,965,977 | 415,401,497 | 414,365,189 | 411,584,851 | 411,261,678 | 411,113,770 | 410,735,780 | · | 408,551,020 | 408,133,807 | 407,265,944 | 408,824,093 | 403,828,955 |
नकदी प्रवाह
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $2M | $2M | $2M | $2M | $6M | $4M | $3M | $5M | $4M | $5M | $5M | $4M | $2M | $6M | $7M | $5M | |
| Amort. of Intangibles | $636.0K | $637.0K | $701.0K | $866.0K | $728.0K | $729.0K | $729.0K | $728.0K | $729.0K | $729.0K | $701.0K | $701.0K | $701.0K | $702.0K | $636.0K | $636.0K | |
| Restructuring | $40.0K | $3M | $4M | $9M | $23M | · | · | · | · | · | $229.0K | $711.0K | $10M | · | $-180.0K | $3M | |
| Operating Cash Flow | $7M | $6M | $15M | $-13M | $17M | $-12M | $-13M | $-2M | $-3M | $-13M | $-645.0K | $7M | $7M | $-7M | $2M | $-18M | |
| Investing Cash Flow | $6M | $-8M | $-4M | $-12M | $12M | $12M | $-23M | $-57M | $5M | $29M | $-71M | $31M | $34M | $-20M | $-28M | $31M | |
| Stock Issued | · | · | · | · | · | · | · | $0 | · | · | · | $0 | · | · | · | $0 | |
| Financing Cash Flow | $-247.0K | $-2M | $-4.0K | $-248.0K | $-663.0K | $-1M | $17.0K | $-68.0K | $34.0K | $-1M | $83.0K | $-277.0K | $60.0K | $364.0K | $38.0K | $-156.0K | |
| Net Change in Cash | $12M | $-4M | $12M | $-25M | $28M | $-2M | $-36M | $-59M | $2M | $15M | $-72M | $38M | $42M | $-26M | $-26M | $12M | |
| Taxes Paid | $1M | $2M | $1M | $-1.0K | $-169.0K | $22.0K | $6M | $-1M | $-698.0K | $29.0K | $3M | $-432.0K | $-633.0K | $38.0K | $-292.0K | $622.0K |
लाभप्रदता
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 35.5% | 39.4% | · | 44.7% | 69.2% | 59.8% | · | 38.5% | 63.4% | 56.5% | · | 45.1% | 53.2% | 55.8% | · | 69.9% | |
| Operating Margin | -28.4% | -25.1% | · | -22.4% | -22.0% | -39.9% | · | -59.5% | -0.78% | -24.0% | · | -32.5% | -29.9% | -20.2% | · | -5.7% | |
| Net Margin | -18.1% | -23.3% | · | -15.6% | -19.4% | -37.4% | · | -59.4% | 2.3% | -17.6% | · | -29.2% | -21.9% | -19.1% | · | -5.7% | |
| Pretax Margin | -18.6% | -19.3% | · | -16.3% | -18.5% | -32.4% | · | -50.9% | 4.3% | -15.3% | · | -28.5% | -22.4% | -16.9% | · | -4.3% | |
| EBITDA Margin | -28.4% | -25.1% | · | -22.4% | -22.0% | -39.9% | · | -59.5% | -0.78% | -24.0% | · | -32.5% | -29.9% | -20.2% | · | -5.7% | |
| ROA | -1.2% | -1.6% | · | -1.1% | -1.9% | -2.2% | · | -3.2% | 0.18% | -1.2% | · | -2.2% | -1.9% | -1.8% | · | -0.53% | |
| ROE | -1.7% | -2.3% | · | -1.6% | -2.8% | -3.1% | · | -4.6% | 0.27% | -1.8% | · | -3.4% | -3.1% | -2.7% | · | -0.84% | |
| ROIC | -2.6% | -3.0% | · | -2.3% | -3.6% | -4.1% | · | -5.5% | -0.05% | -2.9% | · | -4.0% | -4.1% | -3.4% | · | -1.2% |
तरलता और शोधन क्षमता
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.7 | 3.5 | · | 3.4 | 3.3 | 3.5 | · | 3.2 | 3.0 | 3.1 | · | 2.7 | 2.6 | 2.8 | · | 2.4 | |
| Quick Ratio | 2.5 | 2.3 | · | 2.3 | 2.2 | 2.4 | · | 2.1 | 1.9 | 1.9 | · | 1.7 | 1.6 | 1.8 | · | 1.5 |
दक्षता
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Receivables Turnover | 0.4 | 0.4 | · | 0.4 | 0.6 | 0.4 | · | 0.4 | 0.5 | 0.5 | · | 0.5 | 0.6 | 0.7 | · | 0.7 |
प्रति शेयर
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $1.06 | $1.07 | · | $1.10 | $1.12 | $1.14 | · | $1.29 | $1.34 | $1.33 | · | $1.35 | $1.39 | $1.44 | · | $1.46 | |
| Revenue / Share | $0.10 | $0.11 | · | $0.12 | $0.18 | $0.10 | · | $0.10 | $0.16 | $0.14 | · | $0.16 | $0.20 | $0.21 | · | $0.22 | |
| Cash Flow / Share | · | $0.02 | · | · | · | $-0.03 | · | · | · | $-0.03 | · | · | · | $-0.02 | · | · | |
| Cash / Share | $0.34 | $0.31 | · | $0.30 | $0.36 | $0.29 | · | $0.38 | $0.53 | $0.52 | · | $0.66 | $0.57 | $0.47 | · | $0.60 | |
| EPS (TTM) | $-0.07 | $-0.08 | · | $-0.21 | $-0.25 | $-0.22 | · | $-0.10 | $-0.09 | $-0.13 | · | $-0.12 | $-0.08 | $-0.22 | · | $-0.24 |
मूल्यांकन (TTM)
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $186M | $217M | · | $227M | $219M | $214M | · | $241M | $265M | $277M | · | $322M | $346M | $361M | · | $423M | |
| Net Income TTM | $-27M | $-34M | · | $-86M | $-104M | $-88M | · | $-39M | $-34M | $-53M | · | $-52M | $-38M | $-91M | · | $-92M | |
| Market Cap | $6.70B | $6.07B | · | $6.81B | $6.74B | $3.73B | · | $5.18B | $5.67B | $7.31B | · | $7.52B | $9.71B | $12.22B | · | $8.80B | |
| P/E | -227.7 | -180.8 | · | -78.0 | -64.9 | -40.9 | · | -126.0 | -153.3 | -136.9 | · | -153.3 | -297.5 | -136.4 | · | -90.8 | |
| P/S | 36.0 | 28.0 | · | 30.1 | 30.7 | 17.4 | · | 21.5 | 21.4 | 26.4 | · | 23.3 | 28.1 | 33.9 | · | 20.8 | |
| P/B | 15.1 | 13.5 | · | 14.8 | 14.5 | 7.9 | · | 9.8 | 10.3 | 13.4 | · | 13.6 | 17.1 | 20.9 | · | 15.0 | |
| P / Tangible Book | 15.5 | 13.9 | · | 15.3 | 15.0 | 8.1 | · | 10.1 | 10.6 | 13.9 | · | 14.1 | 17.7 | 21.7 | · | 15.5 | |
| P / Cash Flow | · | 949.8 | · | · | · | -299.3 | · | · | · | -580.2 | · | · | · | -1743.4 | · | · | |
| Earnings Yield | -0.44% | -0.55% | · | -1.3% | -1.5% | -2.4% | · | -0.79% | -0.65% | -0.73% | · | -0.65% | -0.34% | -0.73% | · | -1.1% |
सबसे हाल की अवधि बाईं ओर · शून्य मान इस प्रकार दिखाए गए हैं ·
वित्तीय विवरण आय विवरण, बैलेंस शीट, नकदी प्रवाह — वार्षिक, पिछले 5 वर्ष
| मेट्रिक | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| राजस्व | $214M | $229M | $307M | $369M | $583M |
| सकल मार्जिन % | 56.6% | 35.6% | 53.9% | · | · |
| परिचालन मार्जिन % | -23.5% | -40.2% | -22.0% | · | · |
| शुद्ध आय | $-39M | $-82M | $-59M | $-106M | $8M |
| तनुकरणित EPS | $-0.09 | $-0.20 | $-0.15 | $-0.26 | $0.02 |
| मेट्रिक | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| वर्तमान अनुपात | 3.3 | 3.3 | 2.8 | · | · |
| त्वरित अनुपात | 2.2 | 2.3 | 1.8 | · | · |
इस स्टेटमेंट के लिए कोई डेटा नहीं
इस स्टेटमेंट को बनाने के लिए अभी पर्याप्त फंडामेंटल्स डेटा नहीं है।
संस्थागत मालिक (13F) 88 फाइलर्स · $64.3M कुल · तिथि अनुसार 30 जून 2026
संस्थान जो अपनी तिमाही SEC फॉर्म 13F में इस स्टॉक को होल्ड करने की रिपोर्ट करते हैं। केवल लॉन्ग पोजीशन; एक ही फाइलर अलग-अलग ऑप्शन लेग्स के लिए दो बार दिखाई दे सकता है। बड़े ऑफसेटिंग पुट/कॉल लेग्स आमतौर पर मार्केट-मेकिंग या हेज्ड इन्वेंट्री को दर्शाते हैं, न कि दिशात्मक विश्वास को।
धारक
88
धारित मूल्य
$64.3M
नई स्थितियाँ
21
बाहर निकली पोजीशन
7
संस्थागत गतिविधि — Q2 2026 बनाम पिछली तिमाही
| नई स्थितियाँ | बाहर निकली पोजीशन | बढ़ाया | घटा हुआ | शुद्ध शेयर परिवर्तन |
|---|---|---|---|---|
| 21 (+13 पिछली तिमाही की तुलना में) | 7 (-12 पिछली तिमाही की तुलना में) | 16 (-3 पिछली तिमाही की तुलना में) | 14 (-1 पिछली तिमाही की तुलना में) | +79K |
Q1 2026 की तुलना में। SEC फॉर्म 13F फाइलिंग तिमाही के अंत के 45 दिनों के भीतर देय होती है, साथ ही देर से फाइल करने वालों के लिए एक छोटा बफर भी होता है — उस विंडो के भीतर आने वाली तिमाहियों को सबसे हालिया पूरी तरह से रिपोर्ट की गई जोड़ी के पक्ष में छोड़ दिया जाता है।
| संस्था | मूल्य | शेयर | % ट्रैक किए गए 13F का | प्रकार |
|---|---|---|---|---|
| Sarissa Capital Management LP | $26673916 | 1673395 | 41.49% | शेयर |
| Kynam Capital Management, LP | $8495733 | 532982 | 13.22% | शेयर |
| MORGAN STANLEY | $3564456 | 223617 | 5.54% | शेयर |
| Waterfront Wealth Inc. | $3183561 | 213949 | 4.95% | शेयर |
| Brooklands Fund Management Ltd | $2741449 | 177325 | 4.26% | शेयर |
| Eversept Partners, LP | $2316018 | 145296 | 3.60% | शेयर |
| MILLENNIUM MANAGEMENT LLC | $1845980 | 115808 | 2.87% | शेयर |
| TWO SIGMA INVESTMENTS, LP | $1602145 | 100511 | 2.49% | शेयर |
| CITADEL ADVISORS LLC | $1520103 | 95364 | 2.36% | शेयर |
| BNP PARIBAS FINANCIAL MARKETS | $1144699 | 71813 | 1.78% | शेयर |
| LCM Capital Management Inc | $818710 | 51362 | 1.27% | शेयर |
| RENAISSANCE TECHNOLOGIES LLC | $771002 | 48369 | 1.20% | शेयर |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $765120 | 48000 | 1.19% | कॉल ऑप्शन |
| JANE STREET GROUP, LLC | $599790 | 37628 | 0.93% | शेयर |
| George Kaiser Family Foundation | $593080 | 37207 | 0.92% | शेयर |
| TWO SIGMA ADVISERS, LP | $516265 | 36995 | 0.80% | शेयर |
| SEI INVESTMENTS CO | $465628 | 29211 | 0.72% | शेयर |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $462276 | 29001 | 0.72% | शेयर |
| STATE STREET CORP | $398755 | 25016 | 0.62% | शेयर |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $385748 | 24200 | 0.60% | पुट ऑप्शन |
| Bleakley Financial Group, LLC | $374670 | 23505 | 0.58% | शेयर |
| AMERIPRISE FINANCIAL INC | $302573 | 18982 | 0.47% | शेयर |
| State of New Jersey Common Pension Fund D | $300931 | 18879 | 0.47% | शेयर |
| CITADEL ADVISORS LLC | $299672 | 18800 | 0.47% | पुट ऑप्शन |
| COMMONWEALTH OF PENNSYLVANIA PUBLIC SCHOOL EMPLS RETRMT SYS | $292818 | 18370 | 0.46% | शेयर |
| RAYMOND JAMES FINANCIAL INC | $289550 | 18165 | 0.45% | शेयर |
| R Squared Ltd | $269992 | 16938 | 0.42% | शेयर |
| State of Tennessee, Department of Treasury | $239164 | 15004 | 0.37% | शेयर |
| Quadrature Capital Ltd | $236581 | 14842 | 0.37% | शेयर |
| Quinn Opportunity Partners LLC | $228022 | 14305 | 0.35% | शेयर |
| Cubist Systematic Strategies, LLC | $224390 | 13699 | 0.35% | शेयर |
| WELLS FARGO & COMPANY/MN | $221773 | 13913 | 0.34% | शेयर |
| EntryPoint Capital, LLC | $194882 | 12226 | 0.30% | शेयर |
| Jump Financial, LLC | $191407 | 12008 | 0.30% | शेयर |
| GEODE CAPITAL MANAGEMENT, LLC | $187629 | 11771 | 0.29% | शेयर |
| OSAIC HOLDINGS, INC. | $184333 | 11565 | 0.29% | शेयर |
| NJ State Employees Deferred Compensation Plan | $178542 | 10900 | 0.28% | शेयर |
| Verdad Advisers, LP | $166270 | 10431 | 0.26% | शेयर |
| CITADEL ADVISORS LLC | $164182 | 10300 | 0.26% | कॉल ऑप्शन |
| UBS Group AG | $160404 | 10063 | 0.25% | शेयर |
| Steward Partners Investment Advisory, LLC | $142025 | 8910 | 0.22% | शेयर |
| NEW YORK STATE COMMON RETIREMENT FUND | $121224 | 7605 | 0.19% | शेयर |
| NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | $92038 | 5774 | 0.14% | शेयर |
| Federation des caisses Desjardins du Quebec | $73518 | 4615 | 0.11% | शेयर |
| RHUMBLINE ADVISERS | $59498 | 3733 | 0.09% | शेयर |
| NATIONAL BANK OF CANADA /FI/ | $40137 | 2518 | 0.06% | शेयर |
| ROYAL BANK OF CANADA | $30000 | 1877 | 0.05% | शेयर |
| GAMMA Investing LLC | $25121 | 1576 | 0.04% | शेयर |
| NewEdge Advisors, LLC | $21471 | 1347 | 0.03% | शेयर |
| Farther Finance Advisors, LLC | $15271 | 958 | 0.02% | शेयर |
कार्यकर्ता और 5%+ मालिक 35 होल्डिंग्स
जिन निवेशकों ने SEC शेड्यूल 13D दाखिल किया है — जारीकर्ता को प्रभावित करने के इरादे से 5% से अधिक लाभकारी स्वामित्व (कार्यकर्ता दांव, बोर्ड अभियान, M&A)। प्रत्येक पंक्ति उस फाइलर की स्थिति की सबसे हालिया ज्ञात स्थिति दिखाती है।
| फाइलर | दाखिल किया | दांव | स्थिति | उद्देश्य | फाइलिंग |
|---|---|---|---|---|---|
| Alexander J Denner, Sarissa Capital Management LP | 27 अगस्त 2026 | 6.09% | संशोधन | · | SEC |
| Sarissa Capital Management LP, Alexander J Denner ×3 फाइलिंग | 25 मार्च 2025 | 8.08% | संशोधन | बोर्ड अभियान | SEC |
| 28 फ़रवरी 2023 | · | प्रारंभिक फाइलिंग | · | SEC | |
| 27 फ़रवरी 2023 | · | प्रारंभिक फाइलिंग | · | SEC | |
| 21 फ़रवरी 2023 | · | प्रारंभिक फाइलिंग | · | SEC | |
| OR ×6 फाइलिंग | 15 फ़रवरी 2023 | · | प्रारंभिक फाइलिंग | · | SEC |
| 14 फ़रवरी 2023 | · | प्रारंभिक फाइलिंग | · | SEC | |
| 10 फ़रवरी 2023 | · | प्रारंभिक फाइलिंग | · | SEC | |
| 19 जनवरी 2023 | · | प्रारंभिक फाइलिंग | · | SEC | |
| 16 जून 2022 | · | प्रारंभिक फाइलिंग | · | SEC | |
| Sofinnova Venture Partners VII, L.P. (“SVP VII”), Sofinnova Management VII, L.L.C. (“SM VII”), Dr. Michael F. Powell (“Powell”), Dr. James I. Healy (“Healy”), Eric P. Buatois (“Buatois”) ×4 फाइलिंग | 23 अगस्त 2013 | · | प्रारंभिक फाइलिंग | निष्क्रिय निवेश | SEC |
| Abingworth LLP 98-051-8585, Abingworth Bioventures V Co-Invest Growth Equity Fund LP 98-057-9772, Abingworth Bioventures V L.P. 98-051-8587, Abingworth Bioequities Master Fund Limited 66-066-0960 ×10 फाइलिंग | 22 जुलाई 2013 | · | प्रारंभिक फाइलिंग | बोर्ड अभियान | SEC |
| Boxer Capital, LLC, Boxer Asset Management Inc., Joseph Lewis ×4 फाइलिंग | 24 अगस्त 2011 | · | प्रारंभिक फाइलिंग | · | SEC |
| OrbiMed Advisors LLC, OrbiMed Capital GP III LLC, Samuel D. Isaly ×14 फाइलिंग | 28 अप्रैल 2011 | · | प्रारंभिक फाइलिंग | · | SEC |
| Fountain Healthcare Partners Fund 1, L.P. (“ Fountain ”), Fountain Healthcare Partners Ltd., Manus Rogan, Aidan King, Ena Prosser, Justin Lynch ×2 फाइलिंग | 10 दिसमबर 2010 | · | प्रारंभिक फाइलिंग | · | SEC |
| Longitude Capital Partners, LLC (2), Longitude Venture Partners, L.P. (2), Longitude Capital Associates, L.P. (2), Patrick G. Enright (2), Juliet Tammenoms Bakker (2) | 26 अक्टूबर 2010 | · | प्रारंभिक फाइलिंग | · | SEC |
| Panorama Capital, L.P. (“Panorama”), Panorama Capital Management, LLC, Christopher J. Albinson, Rodney A. Ferguson, Shahan D. Soghikian, Damion Wicker | 29 जनवरी 2010 | · | प्रारंभिक फाइलिंग | · | SEC |
| Thomas, McNerney & Partners II, L.P. (“TM&P”), TMP Nominee II, LLC (“TMPN”), TMP Associates II, L.P. (“TMPA”), Thomas, McNerney & Partners II, LLC (“TM&P II”), James Thomas, Pete McNerney, Alex Zisson, Pratik Shah, Dr. Eric Aguiar | 5 जनवरी 2010 | · | प्रारंभिक फाइलिंग | · | SEC |
| Sofinnova Venture Partners VII, L.P. (“ Sofinnova ”), Sofinnova Management VII, L.L.C., Michael F. Powell, Ph.D., Dr. James I. Healy, Eric P. Buatois, Caduceus Private Investments III, LP (“ Caduceus ”), OrbiMed Capital GP III LLC, OrbiMed Associates III, LP (“ OrbiMed ”), OrbiMed Advisors LLC, Samuel D. Isaly, Longitude Venture Partners, L.P. (“ Longitude ”), Longitude Capital Partners, LLC, Patrick Enright, Juliet Tammenoms Bakker, Longitude Capital Associates, L.P., Fountain Healthcare Partners Fund 1, L.P. (“ Fountain ”), Fountain Healthcare Partners Ltd., Manus Rogan, Aidan King, Ena Prosser, Justin Lynch ×3 फाइलिंग | 27 अक्टूबर 2009 | · | प्रारंभिक फाइलिंग | बोर्ड अभियान | SEC |
| अघोषित रिपोर्टिंग व्यक्ति, अघोषित रिपोर्टिंग व्यक्ति, अघोषित रिपोर्टिंग व्यक्ति | 26 अक्टूबर 2009 | · | प्रारंभिक फाइलिंग | बोर्ड अभियान | SEC |
| 27 जुलाई 2009 | · | प्रारंभिक फाइलिंग | · | SEC | |
| Thomas G. Lynch (2) | 28 अप्रैल 2006 | · | प्रारंभिक फाइलिंग | · | SEC |
| Amarin Investment Holding Limited (2) ×2 फाइलिंग | 28 अप्रैल 2006 | · | प्रारंभिक फाइलिंग | · | SEC |
| Simon G. Kukes (2) | 10 जनवरी 2006 | · | प्रारंभिक फाइलिंग | · | SEC |
| अघोषित रिपोर्टिंग व्यक्ति | 1 जुलाई 2005 | · | प्रारंभिक फाइलिंग | निष्क्रिय निवेश | SEC |
| अघोषित रिपोर्टिंग व्यक्ति, अघोषित रिपोर्टिंग व्यक्ति | 8 जून 2005 | · | प्रारंभिक फाइलिंग | निष्क्रिय निवेश | SEC |
| अघोषित रिपोर्टिंग व्यक्ति, अघोषित रिपोर्टिंग व्यक्ति, अघोषित रिपोर्टिंग व्यक्ति | 14 दिसमबर 2004 | · | प्रारंभिक फाइलिंग | · | SEC |
| अघोषित रिपोर्टिंग व्यक्ति, अघोषित रिपोर्टिंग व्यक्ति | 10 नवमबर 2004 | · | प्रारंभिक फाइलिंग | निष्क्रिय निवेश | SEC |
| अघोषित रिपोर्टिंग व्यक्ति | 2 नवमबर 2004 | · | प्रारंभिक फाइलिंग | · | SEC |
| अघोषित रिपोर्टिंग व्यक्ति | 2 नवमबर 2004 | · | प्रारंभिक फाइलिंग | · | SEC |
| अघोषित रिपोर्टिंग व्यक्ति | 2 नवमबर 2004 | · | प्रारंभिक फाइलिंग | · | SEC |
| अघोषित रिपोर्टिंग व्यक्ति | 2 नवमबर 2004 | · | प्रारंभिक फाइलिंग | · | SEC |
| अघोषित रिपोर्टिंग व्यक्ति, अघोषित रिपोर्टिंग व्यक्ति, अघोषित रिपोर्टिंग व्यक्ति, अघोषित रिपोर्टिंग व्यक्ति | 17 दिसमबर 2001 | · | प्रारंभिक फाइलिंग | निष्क्रिय निवेश | SEC |
| अघोषित रिपोर्टिंग व्यक्ति, अघोषित रिपोर्टिंग व्यक्ति, अघोषित रिपोर्टिंग व्यक्ति, अघोषित रिपोर्टिंग व्यक्ति, अघोषित रिपोर्टिंग व्यक्ति, अघोषित रिपोर्टिंग व्यक्ति | 28 सितमबर 2001 | · | प्रारंभिक फाइलिंग | निष्क्रिय निवेश | SEC |
| अघोषित रिपोर्टिंग व्यक्ति | 1 फ़रवरी 2001 | · | प्रारंभिक फाइलिंग | निष्क्रिय निवेश | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
कंपनी के अंदरूनी सूत्र 43 इनसाइडर्स · 18 अधिकारी · 27 निदेशक
| अंदरूनी | भूमिका | अंतिम गतिविधि | शेयरों का स्वामित्व | खरीद 12m | बिक्री 12m | नेट 12m |
|---|---|---|---|---|---|---|
| Aaron Berg | President and CEO | 26 जून 2026 M | 85648 | 0 | 0 | $0 |
| Patrick Holt | President and CEO | 22 जनवरी 2024 P | 314426 | 0 | 0 | $0 |
| Karim Mikhail | President and CEO | 21 फ़रवरी 2023 A | 283507 | 0 | 0 | $0 |
| John F Thero | President and CEO | 30 जुलाई 2021 M | 3252752 | 0 | 0 | $0 |
| Peter L. Fishman | SVP, CFO | 1 अगस्त 2026 A | 7619 | 0 | 0 | $0 |
| Thomas Charles Reilly | EVP and CFO | 1 जुलाई 2024 M | 94305 | 0 | 0 | $0 |
| Michael Wayne Kalb | SVP and CFO | 29 जुलाई 2022 M | 337314 | 0 | 0 | $0 |
| David Paul Keenan | EVP, Chief Operating Officer | 1 जुलाई 2026 A | 13470 | 0 | 0 | $0 |
| Jonathan Provoost | EVP, Chief Legal Officer | 1 जुलाई 2026 A | 4624 | 0 | 0 | $0 |
| Steven B Ketchum | EVP, Chief Scientific Officer | 1 जुलाई 2026 A | 42680 | 0 | 0 | $0 |
| Jason M. Marks | EVP,Chief Global Legal Officer | 19 अगस्त 2022 M | 21917 | 0 | 0 | $0 |
| Joseph T Kennedy | General Counsel | 30 जुलाई 2021 M | 317860 | 0 | 0 | $0 |
| Mark Salyer | Chief Commercial Officer | 1 फ़रवरी 2018 A | · | 0 | 0 | $0 |
| Michael James Farrell | VP, Finance | 1 फ़रवरी 2016 A | 30190 | 0 | 0 | $0 |
| Paul Huff | Chief Commercial Officer | 26 जुलाई 2012 A | 0 | 0 | 0 | $0 |
| Stuart D Sedlack | Senior Vice President | 26 जुलाई 2012 A | 0 | 0 | 0 | $0 |
| Paresh Soni | SVP and Head of Development | 1 फ़रवरी 2012 A | 0 | 0 | 0 | $0 |
| Frederick W Ahlholm | Vice President Finance | 1 फ़रवरी 2012 A | 0 | 0 | 0 | $0 |
| Oliver O'Connor | निदेशक | 18 अप्रैल 2026 M | 801 | 0 | 0 | $0 |
| Paul Cohen | निदेशक | 18 अप्रैल 2026 M | 836 | 0 | 0 | $0 |
| Diane E. Sullivan | निदेशक | 18 अप्रैल 2026 M | 836 | 0 | 0 | $0 |
| Louis Sterling III | निदेशक | 18 अप्रैल 2026 M | 4049 | 0 | 0 | $0 |
| Patrice Eadon Bonfiglio | निदेशक | 18 अप्रैल 2026 M | 836 | 0 | 0 | $0 |
| Keith Horn | निदेशक | 18 अप्रैल 2026 M | 836 | 0 | 0 | $0 |
| Odysseas D Kostas | निदेशक | 18 अप्रैल 2026 M | 836 | 0 | 0 | $0 |
| Mark Dipaolo | निदेशक | 18 अप्रैल 2025 M | 401 | 0 | 0 | $0 |
| Olsen Per Wold | निदेशक | 10 जनवरी 2023 M | 171027 | 0 | 0 | $0 |
| Murray Stewart | निदेशक | 9 जनवरी 2023 A | · | 0 | 0 | $0 |
| Adam Mark Berger | निदेशक | 20 अक्टूबर 2022 A | · | 0 | 0 | $0 |
| Geraldine Murphy | निदेशक | 20 अक्टूबर 2022 A | · | 0 | 0 | $0 |
| Alfonso G Zulueta | निदेशक | 27 जून 2022 A | · | 0 | 0 | $0 |
| Erin S. Enright | निदेशक | 27 जून 2022 A | · | 0 | 0 | $0 |
| Kristine Peterson | निदेशक | 27 जून 2022 A | 0 | 0 | 0 | $0 |
| Patrick J O'Sullivan | निदेशक | 27 जून 2022 A | · | 0 | 0 | $0 |
| Lars Ekman | निदेशक | 27 जून 2022 A | 0 | 0 | 0 | $0 |
| VAN HEEK G JAN | निदेशक | 27 जून 2022 A | 14168 | 0 | 0 | $0 |
| Joseph S Zakrzewski | निदेशक | 15 दिसमबर 2021 P | 196547 | 0 | 0 | $0 |
| David M Stack | निदेशक | 14 जून 2021 A | 40000 | 0 | 0 | $0 |
| Dr. James I. Healy | निदेशक | 11 जुलाई 2016 A | 90000 | 0 | 0 | $0 |
| GORDON CARL L | निदेशक | 4 सितमबर 2012 S | 5700 | 0 | 0 | $0 |
| Joseph Anderson | निदेशक | 10 जुलाई 2012 A | 11683 | 0 | 0 | $0 |
| David W Feigal Jr | निदेशक | 12 जुलाई 2011 A | · | 0 | 0 | $0 |
| Abingworth LLP | 10% मालिक | 19 अप्रैल 2012 S | 1599168 | 0 | 0 | $0 |
SEC फॉर्म 3/4/5 फाइलिंग से अंदरूनी सूत्र; नेट = केवल ओपन-मार्केट P/S
AMRN विश्लेषक सर्वसम्मति तेजी और मंदी के विश्लेषक राय, 12-महीने का मूल्य लक्ष्य, अपसाइड
रेटिंग · 7 विश्लेषक
बेचें
मध्यिका लक्ष्य
$12.50
+1.2%
0 0.0%
मजबूत खरीद
0 0.0%
खरीदें
2 28.6%
होल्ड
3 42.9%
बेचें
2 28.6%
मजबूत बिक्री
12-महीने का मूल्य लक्ष्य
2 विश्लेषक · 2026-10-03माध्य लक्ष्य $12.50 +1.2%
अभी
वर्तमान मूल्य $12.35
निम्न$12.00
माध्य$12.50
उच्च$13.00
सहकर्मी तुलना (GICS उप-उद्योग) प्रमुख मेट्रिक्स बनाम सेक्टर के साथी
वित्तीय वर्ष के आधार पर, प्रत्येक कंपनी के पिछले वित्तीय वर्ष के अंत के बंद भाव के अनुसार कीमतें।
मेरे मेट्रिक्स आपकी व्यक्तिगत वॉचलिस्ट — पूर्ण फंडामेंटल से चयनित पंक्तियाँ
उन मेट्रिक्स को चुनें जो आपके लिए मायने रखते हैं — ऊपर फुल फंडामेंटल्स में किसी भी पंक्ति के बगल में + पर क्लिक करें।
आपका चयन सहेजा गया है और यह सभी टिकर में आपके साथ रहता है।
स्रोत: SEC 10-Q जुल 29, 2026 को फाइल किया गया